

ICMJE DISCLOSURE FORM

Date: 2/3/2023

Your Name: Shoucheng Ma

Manuscript Title: Toripalimab with fruquintinib in the third-line treatment of refractory advanced metastatic colorectal cancer: results of a single-arm, single-center, prospective, phase II clinical study

Manuscript number (if known): JGO-23-108

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This study is sponsored by HUTCHMED Limited and Shanghai Junshi Biosciences	This study is sponsored by HUTCHMED Limited and Shanghai Junshi Biosciences
		Chao Zhao and Zheng Wang from HUTCHMED Limited contributed to the data analysis and review of the manuscript.	Chao Zhao and Zheng Wang from HUTCHMED Limited contributed to the data analysis and review of the manuscript.
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<u>None</u>	<u>None</u>
3	Royalties or licenses	<u>None</u>	<u>None</u>

4	Consulting fees	___ None	___ None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	___ None	___ None
6	Payment for expert testimony	___ None	___ None
7	Support for attending meetings and/or travel	___ None	___ None
8	Patents planned, issued or pending	___ None	___ None
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	___ None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	___ None
11	Stock or stock options	___ None	___ None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	___ None	___ None
13	Other financial or non-financial interests	___ None	___ None

Please summarize the above conflict of interest in the following box:

I have completed the ICMJE uniform disclosure form and this study is sponsored by HUTCHMED Limited and Shanghai Junshi Biosciences. I have no other conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 2/3/2023

Your Name: Rui Chen

Manuscript Title: Toripalimab with fruquintinib in the third-line treatment of refractory advanced metastatic colorectal cancer: results of a single-arm, single-center, prospective, phase II clinical study

Manuscript number (if known): JGO-23-108

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This study is sponsored by HUTCHMED Limited and Shanghai Junshi Biosciences	This study is sponsored by HUTCHMED Limited and Shanghai Junshi Biosciences
		Chao Zhao and Zheng Wang from HUTCHMED Limited contributed to the data analysis and review of the manuscript.	Chao Zhao and Zheng Wang from HUTCHMED Limited contributed to the data analysis and review of the manuscript.
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<u>None</u>	<u>None</u>
3	Royalties or licenses	<u>None</u>	<u>None</u>

4	Consulting fees	___ None	___ None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	___ None	___ None
6	Payment for expert testimony	___ None	___ None
7	Support for attending meetings and/or travel	___ None	___ None
8	Patents planned, issued or pending	___ None	___ None
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	___ None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	___ None
11	Stock or stock options	___ None	___ None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	___ None	___ None
13	Other financial or non-financial interests	___ None	___ None

Please summarize the above conflict of interest in the following box:

I have completed the ICMJE uniform disclosure form and this study is sponsored by HUTCHMED Limited and Shanghai Junshi Biosciences. I have no other conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 2/3/2023
 Your Name: Lin Duan
 Manuscript Title: Toripalimab with fruquintinib in the third-line treatment of refractory advanced metastatic colorectal cancer: results of a single-arm, single-center, prospective, phase II clinical study
 Manuscript number (if known): JGO-23-108

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the **current manuscript only**.

The author's relationships/activities/interests should be **defined broadly**. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This study is sponsored by HUTCHMED Limited and Shanghai Junshi Biosciences.	This study is sponsored by HUTCHMED Limited and Shanghai Junshi Biosciences.
		Chao Zhao and Zheng Wang from HUTCHMED Limited contributed to the data analysis and review of the manuscript.	Chao Zhao and Zheng Wang from HUTCHMED Limited contributed to the data analysis and review of the manuscript.
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	None
3	Royalties or licenses	None	None

4	Consulting fees	___ None	___ None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	___ None	___ None
6	Payment for expert testimony	___ None	___ None
7	Support for attending meetings and/or travel	___ None	___ None
8	Patents planned, issued or pending	___ None	___ None
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	___ None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	___ None
11	Stock or stock options	___ None	___ None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	___ None	___ None
13	Other financial or non-financial interests	___ None	___ None

Please summarize the above conflict of interest in the following box:

I have completed the ICMJE uniform disclosure form and this study is sponsored by HUTCHMED Limited and Shanghai Junshi Biosciences. I have no other conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 2/3/2023

Your Name: Chunmei Li

Manuscript Title: Toripalimab with fruquintinib in the third-line treatment of refractory advanced metastatic colorectal cancer: results of a single-arm, single-center, prospective, phase II clinical study

Manuscript number (if known): JGO-23-108

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This study is sponsored by HUTCHMED Limited and Shanghai Junshi Biosciences.	This study is sponsored by HUTCHMED Limited and Shanghai Junshi Biosciences.
		Chao Zhao and Zheng Wang from HUTCHMED Limited contributed to the data analysis and review of the manuscript.	Chao Zhao and Zheng Wang from HUTCHMED Limited contributed to the data analysis and review of the manuscript.
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<u>None</u>	<u>None</u>

3	Royalties or licenses	___ None	___ None
4	Consulting fees	___ None	___ None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	___ None	___ None
6	Payment for expert testimony	___ None	___ None
7	Support for attending meetings and/or travel	___ None	___ None
8	Patents planned, issued or pending	___ None	___ None
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	___ None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	___ None
11	Stock or stock options	___ None	___ None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	___ None	___ None
13	Other financial or non-financial interests	___ None	___ None

Please summarize the above conflict of interest in the following box:

I have completed the ICMJE uniform disclosure form and this study is sponsored by HUTCHMED Limited and Shanghai Junshi Biosciences. I have no other conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 2/3/2023
 Your Name: Tianning Yang
 Manuscript Title: Toripalimab with fruquintinib in the third-line treatment of refractory advanced metastatic colorectal cancer: results of a single-arm, single-center, prospective, phase II clinical study
 Manuscript number (if known): JGO-23-108

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the **current manuscript only**.

The author's relationships/activities/interests should be **defined broadly**. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This study is sponsored by HUTCHMED Limited and Shanghai Junshi Biosciences.	This study is sponsored by HUTCHMED Limited and Shanghai Junshi Biosciences.
		Chao Zhao and Zheng Wang from HUTCHMED Limited contributed to the data analysis and review of the manuscript.	Chao Zhao and Zheng Wang from HUTCHMED Limited contributed to the data analysis and review of the manuscript.
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	None
3	Royalties or licenses	None	None

4	Consulting fees	___ None	___ None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	___ None	___ None
6	Payment for expert testimony	___ None	___ None
7	Support for attending meetings and/or travel	___ None	___ None
8	Patents planned, issued or pending	___ None	___ None
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	___ None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	___ None
11	Stock or stock options	___ None	___ None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	___ None	___ None
13	Other financial or non-financial interests	___ None	___ None

Please summarize the above conflict of interest in the following box:

I have completed the ICMJE uniform disclosure form and this study is sponsored by HUTCHMED Limited and Shanghai Junshi Biosciences. I have no other conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 2/3/2023
 Your Name: Jiankai Wang
 Manuscript Title: Toripalimab with fruquintinib in the third-line treatment of refractory advanced metastatic colorectal cancer: results of a single-arm, single-center, prospective, phase II clinical study
 Manuscript number (if known): JGO-23-108

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	I have completed the ICMJE uniform disclosure form and this study is sponsored by HUTCHMED Limited and Shanghai Junshi Biosciences. I have no other conflicts of interest to declare.	I have completed the ICMJE uniform disclosure form and this study is sponsored by HUTCHMED Limited and Shanghai Junshi Biosciences. I have no other conflicts of interest to declare.
		I have completed the ICMJE uniform disclosure form and this study is sponsored by HUTCHMED Limited and Shanghai Junshi Biosciences. I have no other conflicts of interest to declare.	I have completed the ICMJE uniform disclosure form and this study is sponsored by HUTCHMED Limited and Shanghai Junshi Biosciences. I have no other conflicts of interest to declare.

Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	___ None	___ None
3	Royalties or licenses	___ None	___ None
4	Consulting fees	___ None	___ None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	___ None	___ None
6	Payment for expert testimony	___ None	___ None
7	Support for attending meetings and/or travel	___ None	___ None
8	Patents planned, issued or pending	___ None	___ None
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	___ None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	___ None
11	Stock or stock options	___ None	___ None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	___ None	___ None
13	Other financial or non-financial interests	___ None	___ None

Please summarize the above conflict of interest in the following box:

I have completed the ICMJE uniform disclosure form and this study is sponsored by HUTCHMED Limited and Shanghai Junshi Biosciences. I have no other conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 2/3/2023
 Your Name: Da Zhao
 Manuscript Title: Toripalimab with fruquintinib in the third-line treatment of refractory advanced metastatic colorectal cancer: results of a single-arm, single-center, prospective, phase II clinical study
 Manuscript number (if known): JGO-23-108

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This study is sponsored by HUTCHMED Limited and Shanghai Junshi Biosciences.	This study is sponsored by HUTCHMED Limited and Shanghai Junshi Biosciences.
		Chao Zhao and Zheng Wang from HUTCHMED Limited contributed to the data analysis and review of the manuscript.	Chao Zhao and Zheng Wang from HUTCHMED Limited contributed to the data analysis and review of the manuscript.
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	None
3	Royalties or licenses	None	None

4	Consulting fees	___ None	___ None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	___ None	___ None
6	Payment for expert testimony	___ None	___ None
7	Support for attending meetings and/or travel	___ None	___ None
8	Patents planned, issued or pending	___ None	___ None
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	___ None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	___ None
11	Stock or stock options	___ None	___ None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	___ None	___ None
13	Other financial or non-financial interests	___ None	___ None

Please summarize the above conflict of interest in the following box:

I have completed the ICMJE uniform disclosure form and this study is sponsored by HUTCHMED Limited and Shanghai Junshi Biosciences. I have no other conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.